Steatosis as a Cofactor in Other Liver Diseases: Hepatitis C Virus, Alcohol, Hemochromatosis, and Others

Clinics in Liver Disease

Volumn 11, Issue 1, 2007, Pages 173-189

  Clouston, Andrew D ^a   Jonsson, Julie R ^a   Powell, Elizabeth E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INTERFERON; METHOTREXATE; TAMOXIFEN;

ALCOHOL LIVER DISEASE; ANTIVIRAL ACTIVITY; APOPTOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FATTY ACID OXIDATION; FATTY LIVER; HEMOCHROMATOSIS; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; METABOLIC SYNDROME X; OBESITY; OXIDATIVE STRESS; REVIEW; RISK FACTOR; STEATOSIS; TOXIC HEPATITIS; TREATMENT OUTCOME; VIRUS HEPATITIS; WEIGHT REDUCTION;

FATTY LIVER; HEMOCHROMATOSIS; HEPATITIS C; HUMANS; LIVER DISEASES, ALCOHOLIC; OBESITY; RISK FACTORS;

EID: 34249723678     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.02.007     Document Type: Review

References (113)

1. Day C.P., and James O.F.W. Hepatic steatosis: innocent bystander or guilty party?. Hepatology 27 6 (1998) 1463-1466
2. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 6 (2004) 1387-1395
3. Neuschwander-Tetri B.A., and Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37 5 (2003) 1202-1219
4. Lonardo A., Loria P., Adinolfi L.E., et al. Hepatitis C and steatosis: a reappraisal. J Viral Hepat 13 2 (2006) 73-80
5. Bach N., Thung S.N., and Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 15 4 (1992) 572-577
6. Scheuer P.J., Ashrafzadeh P., Sherlock S., et al. The pathology of hepatitis C. Hepatology 15 4 (1992) 567-571
7. Lefkowitch J.H., Schiff E.R., Davis G.L., et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology 104 2 (1993) 595-603
8. Clouston A.D., and Powell E.E. Interaction of non-alcoholic fatty liver disease with other liver diseases. Best Pract Res Clin Gastroenterol 16 5 (2002) 767-781
9. Lonardo A., Adinolfi L.E., Loria P., et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 126 2 (2004) 586-597
10. Czaja A.J., Carpenter H.A., Santrach P.J., et al. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 29 2 (1998) 198-206
11. Hourigan L.F., Macdonald G.A., Purdie D., et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29 4 (1999) 1215-1219
12. Jonsson J.R., Edwards-Smith C.J., Purdie D., et al. Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients. Hepatology 30 (1999) 1531-1532
13. Adinolfi L.E., Gambardella M., Andreana A., et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33 6 (2001) 1358-1364
14. Westin J., Nordlinder H., Lagging M., et al. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 37 6 (2002) 837-842
15. Monto A., Alonzo J., Watson J.J., et al. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 36 3 (2002) 729-736
16. Castera L., Hezode C., Roudot-Thoraval F., et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 52 2 (2003) 288-292
17. Poynard T., Ratziu V., McHutchison J., et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38 1 (2003) 75-85
18. Patton H.M., Patel K., Behling C., et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 40 3 (2004) 484-490
19. Powell E.E., Jonsson J.R., and Clouston A.D. Steatosis: co-factor in other liver diseases. Hepatology 42 1 (2005) 5-13
20. Lonardo A., Lombardini S., Ricchi M., et al. Review article: hepatic steatosis and insulin resistance. Aliment Pharmacol Ther 22 Suppl 2 (2005) 64-70
21. Younossi Z.M., McCullough A.J., Ong J.P., et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 38 8 (2004) 705-709
22. Clouston A.D., Jonsson J.R., Purdie D.M., et al. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 34 2 (2001) 314-320
23. Wyatt J., Baker H., Prasad P., et al. Steatosis and fibrosis in patients with chronic hepatitis C. J Clin Pathol 57 4 (2004) 402-406
24. Powell E.E., Cooksley W.G., Hanson R., et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11 1 (1990) 74-80
25. Caldwell S.H., and Crespo D.M. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 40 4 (2004) 578-584
26. Fabris P., Floreani A., Carlotto A., et al. Impact of liver steatosis on virological response in Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavarin. Aliment Pharmacol Ther 21 9 (2005) 1173-1178
27. Guidi M., Muratori P., Granito A., et al. Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin. Aliment Pharmacol Ther 22 10 (2005) 943-949
28. Bressler B.L., Guindi M., Tomlinson G., et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38 3 (2003) 639-644
29. Lam N.P., Pitrak D., Speralakis R., et al. Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci 42 1 (1997) 178-185
30. Romero-Gomez M., Del Mar Viloria M., Andrade R.J., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128 3 (2005) 636-641
31. D'Souza R., Sabin C.A., and Foster G.R. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 100 7 (2005) 1509-1515
32. Walsh M.J., Jonsson J.R., Richardson M.M., et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 55 4 (2006) 529-535
33. Ueki K., Kadowaki T., and Kahn C.R. Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic steatosis and the metabolic syndrome. Hepatol Res 33 2 (2005) 185-192
34. Barba G., Harper F., Harada T., et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A 94 4 (1997) 1200-1205
35. Moriya K., Yotsuyanagi H., Shintani Y., et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78 Pt 7 (1997) 1527-1531
36. Moriya K., Fujie H., Shintani Y., et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4 9 (1998) 1065-1067
37. Perlemuter G., Sabile A., Letteron P., et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 16 2 (2002) 185-194
38. Rubbia-Brandt L., Quadri R., Abid K., et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 33 1 (2000) 106-115
39. Su A.I., Pezacki J.P., Wodicka L., et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 99 24 (2002) 15669-15674
40. Hickman I.J., Clouston A.D., Macdonald G.A., et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 51 1 (2002) 89-94
41. Rubbia-Brandt L., Fabris P., Paganin S., et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 53 3 (2004) 406-412
42. Farrell G.C., and Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 2 Suppl 1 (2006) S99-S112
43. Larter C.Z., and Farrell G.C. Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat?. J Hepatol 44 2 (2006) 253-261
44. Fartoux L., Poujol-Robert A., Guechot J., et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 54 7 (2005) 1003-1008
45. Shintani Y., Fujie H., Miyoshi H., et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126 3 (2004) 840-848
46. Wang A.Y., Hickman I.J., Richards A.A., et al. High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection. Am J Gastroenterol 100 12 (2005) 2717-2723
47. Petit J.M., Bour J.B., Galland-Jos C., et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 35 2 (2001) 279-283
48. Ratziu V., Munteanu M., Charlotte F., et al. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 39 6 (2003) 1049-1055
49. Muzzi A., Leandro G., Rubbia-Brandt L., et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 42 1 (2005) 41-46
50. Camma C., Bruno S., Di Marco V., et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 43 1 (2006) 64-71
51. Zekry A., McHutchison J.G., and Diehl A.M. Insulin resistance and steatosis in hepatitis C virus infection. Gut 54 7 (2005) 903-906
52. Korenaga M., Wang T., Li Y., et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 280 45 (2005) 37481-37488
53. Koike K., and Miyoshi H. Oxidative stress and hepatitis C viral infection. Hepatol Res 34 (2006) 65-73
54. Cardin R., Saccoccio G., Masutti F., et al. DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study. J Hepatol 34 4 (2001) 587-592
55. Farinati F., Cardin R., Bortolami M., et al. The mechanisms underlying hepatitis C virus genotype 3-mediated liver damage. J Hepatol 39 2 (2003) 292-294
56. Zatloukal K., Stumptner C., Fuchsbichler A., et al. The keratin cytoskeleton in liver diseases. J Pathol 204 4 (2004) 367-376
57. Feldstein A.E., Canbay A., Angulo P., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125 2 (2003) 437-443
58. Walsh M.J., Vanags D.M., Clouston A.D., et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology 39 5 (2004) 1230-1238
59. Bantel H., Lugering A., Heidemann J., et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 40 5 (2004) 1078-1087
60. Ratziu V., Saboury M., and Poynard T. Worsening of steatosis and fibrosis progression. Gut 52 9 (2003) 1386-1387
61. Hui J.M., Sud A., Farrell G.C., et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 125 6 (2003) 1695-1704
62. Sud A., Hui J.M., Farrell G.C., et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 39 5 (2004) 1239-1247
63. Hickman I.J., Powell E.E., Prins J.B., et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 39 6 (2003) 1042-1048
64. Svegliati-Baroni G., Ridolfi F., Di Sario A., et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 29 6 (1999) 1743-1751
65. Paradis V., Perlemuter G., Bonvoust F., et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 34 4 Pt 1 (2001) 738-744
66. Romero-Gomez M., Castellano-Megias V.M., Grande L., et al. Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol 98 5 (2003) 1135-1141
67. Piche T., Vandenbos F., Abakar-Mahamat A., et al. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat 11 1 (2004) 91-96
68. Hui J.M., Hodge A., Farrell G.C., et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 40 1 (2004) 46-54
69. Kaser S., Moschen A., Cayon A., et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54 1 (2005) 117-121
70. Jonsson J.R., Moschen A.R., Hickman I.J., et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 43 6 (2005) 929-936
71. Zhang B.H., Hornsfield B.P., and Farrell G.C. Chronic ethanol administration to rats decreases receptor-operated mobilization of intracellular ionic calcium in cultured hepatocytes and inhibits 1,4,5-inositol trisphosphate production: relevance to impaired liver regeneration. J Clin Invest 98 5 (1996) 1237-1244
72. Yang S.Q., Lin H.Z., Mandal A.K., et al. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology. Hepatology 34 4 Pt 1 (2001) 694-706
73. Roskams T., Yang S.Q., Koteish A., et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 163 4 (2003) 1301-1311
74. Yang S., Koteish A., Lin H., et al. Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. Hepatology 39 2 (2004) 403-411
75. Sell S. Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology 33 3 (2001) 738-750
76. Marra F., DeFranco R., Grappone C., et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 152 2 (1998) 423-430
77. Grappone C., Pinzani M., Parola M., et al. Expression of platelet-derived growth factor in newly formed cholangiocytes during experimental biliary fibrosis in rats. J Hepatol 31 1 (1999) 100-109
78. Lamireau T., Le Bail B., Boussarie L., et al. Expression of collagens type I and IV, osteonectin and transforming growth factor beta-1 (TGFbeta1) in biliary atresia and paucity of intrahepatic bile ducts during infancy. J Hepatol 31 2 (1999) 248-255
79. Ramm G.A., Hoskins A.C., Greco S.A., et al. Signals for hepatic fibrogenesis in pediatric cholestatic liver disease: review and hypothesis. Comp Hepatol 3 Suppl 1 (2004) S5
80. Clouston A.D., Powell E.E., Walsh M.J., et al. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 41 4 (2005) 809-818
81. Richardson M.M., Jonsson J.R., Brunt E.M., et al. Hepatic progenitor cell expansion and a periportal ductular reaction in NAFLD-relationship with impaired hepatocyte proliferation and fibrosis, and reversal with treatment. Hepatology 42 (2005) 611A
82. Hickman I.J., Jonsson J.R., Prins J.B., et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53 3 (2004) 413-419
83. Qayyum A., Goh J.S., Kakar S., et al. Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques-initial experience. Radiology 237 (2005) 507-511
84. Bellentani S., and Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 35 4 (2001) 531-537
85. Raynard B., Balian A., Fallik D., et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 35 3 (2002) 635-638
86. Naveau S., Giraud V., Borotto E., et al. Excess weight risk factor for alcoholic liver disease. Hepatology 25 1 (1997) 108-111
87. Diehl A.M. Obesity and alcoholic liver disease. Alcohol 34 1 (2004) 81-87
88. Lieber C.S. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol 34 1 (2004) 9-19
89. Mezey E. Dietary fat and alcoholic liver disease. Hepatology 28 4 (1998) 901-905
90. Robertson G., Leclercq I., and Farrell G.C. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 281 5 (2001) G1135-G1139
91. Bunout D., Munoz C., Lopez M., et al. Interleukin 1 and tumor necrosis factor in obese alcoholics compared with normal-weight patients. Am J Clin Nutr 63 3 (1996) 373-376
92. Powell E.E., Ali A., Clouston A.D., et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology 129 6 (2005) 1937-1943
93. Fletcher L.M., Bridle K.R., and Crawford D.H. Effect of alcohol on iron storage diseases of the liver. Best Pract Res Clin Gastroenterol 17 4 (2003) 663-677
94. Mendler M.H., Turlin B., Moirand R., et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 117 5 (1999) 1155-1163
95. George D.K., Goldwurm S., MacDonald G.A., et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114 2 (1998) 311-318
96. Bonkovsky H.L., Jawaid Q., Tortorelli K., et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 31 3 (1999) 421-429
97. Chitturi S., Weltman M., Farrell G.C., et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 36 1 (2002) 142-149
98. Bugianesi E., Manzini P., D'Antico S., et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39 1 (2004) 179-187
99. Loria P., Lonardo A., and Carulli N. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39 6 (2004) 1748
100. Vigano M., Vergani A., Trombini P., et al. Insulin resistance influences iron metabolism and hepatic steatosis in type II diabetes. Gastroenterology 118 5 (2000) 986-987
101. Piperno A., Vergani A., Salvioni A., et al. Effects of venesections and restricted diet in patients with the insulin-resistance hepatic iron overload syndrome. Liver Int 24 5 (2004) 471-476
102. Facchini F.S., Hua N.W., and Stoohs R.A. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 122 4 (2002) 931-939
103. Valenti L., Fracanzani A.L., and Fargion S. Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate-intolerance. Gastroenterology 124 (2003) 866
104. Boelsterli U.A. Animal models of human disease in drug safety assessment. J Toxicol Sci 28 3 (2003) 109-121
105. Pessayre D., Mansouri A., and Fromenty B. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 282 2 (2002) G193-G199
106. Farrell G.C. Drugs and steatohepatitis. Semin Liver Dis 22 2 (2002) 185-194
107. Bruno S., Maisonneuve P., Castellana P., et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 330 7497 (2005) 932-935
108. Langman G., Hall P.M., and Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 16 12 (2001) 1395-1401
109. Brunt E.M., Ramrakhiani S., Cordes B.G., et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 16 1 (2003) 49-56
110. Thomopoulos K.C., Arvaniti V., Tsamantas A.C., et al. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol 18 3 (2006) 233-237
111. Thomas D.L. Growing importance of liver disease in HIV-infected persons. Hepatology 43 2 Suppl 1 (2006) S221-S229
112. Qurishi N., Kreuzberg C., Luchters G., et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362 9397 (2003) 1708-1713
113. Bowlus C.L., Willner I., Zern M.A., et al. Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. Clin Gastroenterol Hepatol 3 4 (2005) 390-396